International Urology and Nephrology

, Volume 42, Issue 1, pp 165–171

Vitamin D and cardiovascular risk

Nephrology - Review

Abstract

Vitamin D deficiency results in abnormal mineralization of bones and has resulted in prevention programs for children with supplementation when they are breast fed. Further activities of vitamin D relate to defence of microbial infections, e.g. tuberculosis, prevention of cancer, contractility of muscle cells and counteraction of congestive heart failure. Given early reports in the 1960s on deleterious effects of vitamin D supplementation in rodents, that is ectopic media ossification of arterial vessels, a pro-atherogenic function had been anticipated for humans as well. However, cross-sectional studies reveal that vitamin D deficiency in humans is associated with elevated blood pressure and propagation of atherogenesis. These contradictory findings on the progression of atherosclerosis may be reconciled by dissecting the activation mechanism(s) of vitamin D in rodents versus humans. Notably, novel findings convincingly indicate that vitamin D exerts anti-inflammatory effects. In conclusion, vitamin D supplementation in adults may be regarded as simple means with few potential side effects to prevent atherogenesis or halt its progression and combat arterial hypertension. Adjustment of vitamin D dosing regimens is required in patients with chronic kidney disease; however, prospective clinical trials are urgently needed to guide these recommendations with evidence.

Keywords

Vitamin D Atherosclerosis Hypertension Vascular smooth muscle cells Monocytes Renin 

References

  1. 1.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266CrossRefPubMedGoogle Scholar
  2. 2.
    Bouillon R, Bischoff-Ferrari H, Willett W (2008) Vitamin D and health: perspectives from mice and man. J Bone Miner Res 23:974CrossRefPubMedGoogle Scholar
  3. 3.
    Rammos G, Tseke P, Ziakka S (2008) Vitamin D, the renin-angiotensin system, and insulin resistance. Int Urol Nephrol 40:419CrossRefPubMedGoogle Scholar
  4. 4.
    Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19:1741CrossRefPubMedGoogle Scholar
  5. 5.
    Tian S, Li J, Wang L et al (2007) Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res 56:304CrossRefPubMedGoogle Scholar
  6. 6.
    Raffetseder U, Rauen T, Djudjaj S et al (2009) Differential regulation of chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1. Kidney Int 75:185CrossRefPubMedGoogle Scholar
  7. 7.
    Krohn R, Raffetseder U, Bot I et al (2007) Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 116:1812CrossRefPubMedGoogle Scholar
  8. 8.
    Eleftheriadis T, Antoniadi G, Liakopoulos V et al. (2009) Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells. Int Urol NephrolGoogle Scholar
  9. 9.
    Hass GM, Landerholm W, Hemmens A (1966) Production of calcific athero-arteriosclerosis and thromboarteritis with nicotine, vitamin D and dietary cholesterol. Am J Pathol 49:739PubMedGoogle Scholar
  10. 10.
    Inoue T, Kawashima H (1988) 1, 25-Dihydroxyvitamin D3 stimulates 45Ca2 + -uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem Biophys Res Commun 152:1388CrossRefPubMedGoogle Scholar
  11. 11.
    Micheletti RG, Fishbein GA, Currier JS et al (2008) Monckeberg sclerosis revisited: a clarification of the histologic definition of Monckeberg sclerosis. Arch Pathol Lab Med 132:43PubMedGoogle Scholar
  12. 12.
    Moe SM, O’Neill KD, Duan D et al (2002) Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61:638CrossRefPubMedGoogle Scholar
  13. 13.
    Gottfried E, Rehli M, Hahn J et al (2006) Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem Biophys Res Commun 349:209CrossRefPubMedGoogle Scholar
  14. 14.
    Rostand SG (1997) Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 30:150PubMedGoogle Scholar
  15. 15.
    Melamed ML, Michos ED, Post W et al (2008) 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168:1629CrossRefPubMedGoogle Scholar
  16. 16.
    Krause R, Buhring M, Hopfenmuller W et al (1998) Ultraviolet B and blood pressure. Lancet 352:709CrossRefPubMedGoogle Scholar
  17. 17.
    Sugden JA, Davies JI, Witham MD et al (2008) Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25:320CrossRefPubMedGoogle Scholar
  18. 18.
    Pfeifer M, Begerow B, Minne HW et al (2001) Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86:1633CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou C, Lu F, Cao K et al (2008) Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74:170CrossRefPubMedGoogle Scholar
  20. 20.
    Yuan W, Pan W, Kong J et al (2007) 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282:29821CrossRefPubMedGoogle Scholar
  21. 21.
    Fitzpatrick LA, Bilezikian JP, Silverberg SJ (2008) Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 6:77CrossRefPubMedGoogle Scholar
  22. 22.
    Peterlik M, Cross HS (2005) Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 35:290CrossRefPubMedGoogle Scholar
  23. 23.
    Scragg R, Sowers M, Bell C (2007) Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. Am J Hypertens 20:713CrossRefPubMedGoogle Scholar
  24. 24.
    Wang TJ, Pencina MJ, Booth SL et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503CrossRefPubMedGoogle Scholar
  25. 25.
    Pilz S, Dobnig H, Fischer JE et al (2008) Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 39:2611CrossRefPubMedGoogle Scholar
  26. 26.
    Michos ED, Melamed ML (2008) Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 11:7CrossRefPubMedGoogle Scholar
  27. 27.
    Dobnig H, Pilz S, Scharnagl H et al (2008) Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340CrossRefPubMedGoogle Scholar
  28. 28.
    Melamed ML, Muntner P, Michos ED et al (2008) Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 28:1179CrossRefPubMedGoogle Scholar
  29. 29.
    Pilz S, Marz W, Wellnitz B et al (2008) Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93:3927CrossRefPubMedGoogle Scholar
  30. 30.
    Reis J P, von Muhlen D, Michos E D et al. (2009) Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis, (in press)Google Scholar
  31. 31.
    Kovesdy CP, Kalantar-Zadeh K (2008) Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 40:427CrossRefPubMedGoogle Scholar
  32. 32.
    Wang AY, Lam CW, Sanderson JE et al (2008) Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-year prospective cohort study. Am J Clin Nutr 87:1631PubMedGoogle Scholar
  33. 33.
    Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004CrossRefPubMedGoogle Scholar
  34. 34.
    Teng M, Wolf M, Lowrie E et al (2003) Survival of patients undergoing hemodialysis with pricalcitol or calcitriol therapy. N Engl J Med 349:446CrossRefPubMedGoogle Scholar
  35. 35.
    Teng M, Wolf M, Ofsthun MN et al (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115CrossRefPubMedGoogle Scholar
  36. 36.
    Mosekilde L (2005) Vitamin D and the elderly. Clin Endocrinol (Oxf) 62:265CrossRefGoogle Scholar
  37. 37.
    Daher EF, Silva Junior GB, Queiroz AL et al (2009) Acute kidney injury due to anabolic steroid and vitamin supplement abuse: report of two cases and a literature review. Int Urol Nephrol 41:717CrossRefPubMedGoogle Scholar
  38. 38.
    Taskapan H, Vieth R, Oreopoulos DG (2008) Unusually prolonged vitamin D intoxication after discontinuation of vitamin D: possible role of primary hyperparathyroidism. Int Urol Nephrol 40:801CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, B.V. 2009

Authors and Affiliations

  1. 1.Department of Nephrology and Hypertension & Endocrinology and Metabolic DiseasesOtto-von-Guericke-University MagdeburgMagdeburgGermany

Personalised recommendations